Similar articles for PMID: 15765627

Year	Number of Results
1995	1
1996	4
1997	2
1998	6
1999	3
2000	2
2001	9
2002	8
2003	14
2004	25
2005	19
2006	6
2007	9
2008	4
2009	11
2010	8
2011	16
2012	14
2013	12
2014	26
2015	12
2016	9
2017	11
2018	10
2019	24
2020	23
2021	39
2022	45
2023	15
2024	1

1

Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.

Baggio LL, Drucker DJ. Baggio LL, et al. Treat Endocrinol. 2002;1(2):117-25. doi: 10.2165/00024677-200201020-00005. Treat Endocrinol. 2002. PMID: 15765627 Review.

2

Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.

Drucker DJ. Drucker DJ. Curr Pharm Des. 2001 Sep;7(14):1399-412. doi: 10.2174/1381612013397401. Curr Pharm Des. 2001. PMID: 11472275 Review.

3

Enhancing incretin action for the treatment of type 2 diabetes.

Drucker DJ. Drucker DJ. Diabetes Care. 2003 Oct;26(10):2929-40. doi: 10.2337/diacare.26.10.2929. Diabetes Care. 2003. PMID: 14514604 Review.

4

[Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].

Diamant M, Bunck MC, Heine RJ. Diamant M, et al. Ned Tijdschr Geneeskd. 2004 Sep 25;148(39):1912-7. Ned Tijdschr Geneeskd. 2004. PMID: 15495988 Review. Dutch.

5

Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.

Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C. Gautier JF, et al. Diabetes Metab. 2005 Jun;31(3 Pt 1):233-42. doi: 10.1016/s1262-3636(07)70190-8. Diabetes Metab. 2005. PMID: 16142014 Review.

6

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

Holst JJ, Deacon CF. Holst JJ, et al. Diabetes. 1998 Nov;47(11):1663-70. doi: 10.2337/diabetes.47.11.1663. Diabetes. 1998. PMID: 9792533 Review.

7

Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.

Holst JJ. Holst JJ. Expert Opin Emerg Drugs. 2004 May;9(1):155-66. doi: 10.1517/eoed.9.1.155.32952. Expert Opin Emerg Drugs. 2004. PMID: 15155141 Review.

8

Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.

Nauck MA. Nauck MA. Horm Metab Res. 2004 Nov-Dec;36(11-12):852-8. doi: 10.1055/s-2004-826175. Horm Metab Res. 2004. PMID: 15655719 Review.

9

Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.

Green BD, Gault VA, Irwin N, Mooney MH, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP. Green BD, et al. Biol Chem. 2003 Dec;384(12):1543-51. doi: 10.1515/BC.2003.171. Biol Chem. 2003. PMID: 14719796

10

GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.

Hansotia T, Drucker DJ. Hansotia T, et al. Regul Pept. 2005 Jun 15;128(2):125-34. doi: 10.1016/j.regpep.2004.07.019. Regul Pept. 2005. PMID: 15780432 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

357 results

Results by year